risperidone has been researched along with Pancreatitis in 9 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our previous study suggested that a combination of ulinastatin and risperidone reduced post-ERCP pancreatitis (PEP) compared with ulinastatin alone." | 9.17 | Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial. ( Akiyama, D; Arizumi, T; Hamada, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Nakajima, K; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Tsujino, T; Uchino, R; Yagioka, H; Yamamoto, N; Yanagihara, Y, 2013) |
| " Six patients in the risperidone + ulinastatin group and ten patients in the ulinastatin group developed pancreatitis (5." | 9.17 | The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial. ( Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y, 2013) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 8.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice." | 7.75 | Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. ( Hamada, K; Isayama, H; Kanazashi, S; Takeuchi, K; Yamaguchi, I; Yoshida, M, 2009) |
| "Our previous study suggested that a combination of ulinastatin and risperidone reduced post-ERCP pancreatitis (PEP) compared with ulinastatin alone." | 5.17 | Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial. ( Akiyama, D; Arizumi, T; Hamada, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Nakajima, K; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Tsujino, T; Uchino, R; Yagioka, H; Yamamoto, N; Yanagihara, Y, 2013) |
| " Six patients in the risperidone + ulinastatin group and ten patients in the ulinastatin group developed pancreatitis (5." | 5.17 | The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial. ( Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y, 2013) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 4.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "In a previous article, we showed that a potent serotonin-, 5-hydroxytryptamine-2A (5-HT(2A)) antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice." | 3.75 | Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis. ( Hamada, K; Isayama, H; Kanazashi, S; Takeuchi, K; Yamaguchi, I; Yoshida, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Naguy, A | 1 |
| Roshdy, R | 1 |
| Alamiri, B | 1 |
| Uchino, R | 1 |
| Isayama, H | 3 |
| Tsujino, T | 2 |
| Sasahira, N | 2 |
| Ito, Y | 2 |
| Matsubara, S | 2 |
| Takahara, N | 1 |
| Arizumi, T | 2 |
| Toda, N | 2 |
| Mohri, D | 1 |
| Togawa, O | 2 |
| Yagioka, H | 2 |
| Yanagihara, Y | 1 |
| Nakajima, K | 1 |
| Akiyama, D | 1 |
| Hamada, T | 1 |
| Miyabayashi, K | 1 |
| Mizuno, S | 2 |
| Kawakubo, K | 1 |
| Kogure, H | 2 |
| Sasaki, T | 2 |
| Yamamoto, N | 2 |
| Nakai, Y | 2 |
| Hirano, K | 2 |
| Tada, M | 2 |
| Koike, K | 2 |
| Enns, R | 1 |
| Lee, S | 1 |
| Yamaguchi, I | 1 |
| Hamada, K | 1 |
| Yoshida, M | 1 |
| Kanazashi, S | 1 |
| Takeuchi, K | 1 |
| Ghio, L | 1 |
| Fornaro, G | 1 |
| Rossi, P | 1 |
| Yamamoto, K | 1 |
| Yashima, Y | 1 |
| Hanft, A | 1 |
| Bourgeois, J | 1 |
| Berent, I | 1 |
| Carabeth, J | 1 |
| Cordero, MM | 1 |
| Cordero, R | 1 |
| Sugerman, B | 1 |
| Robinson, D | 1 |
| Cordeiro, Q | 1 |
| Elkis, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000459] | Phase 3 | 0 participants | Interventional | 1986-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for risperidone and Pancreatitis
| Article | Year |
|---|---|
Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial.
Topics: Adult; Aged; Ampulla of Vater; Amylases; Bile Ducts, Intrahepatic; C-Reactive Protein; Cholangiopanc | 2013 |
The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Cholangiopancreatography, Endoscopic Retrograde; Drug Therapy, Co | 2013 |
7 other studies available for risperidone and Pancreatitis
| Article | Year |
|---|---|
Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD.
Topics: Acute Disease; Attention Deficit Disorder with Hyperactivity; Child; Conduct Disorder; Humans; Pancr | 2022 |
Preventing post-ERCP pancreatitis.
Topics: Ampulla of Vater; Bile Ducts, Intrahepatic; Cholangiopancreatography, Endoscopic Retrograde; Female; | 2013 |
Risperidone attenuates local and systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis.
Topics: Acute Disease; Amylases; Animals; Anti-Inflammatory Agents; Choline Deficiency; Ethionine; Female; I | 2009 |
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report.
Topics: Antipsychotic Agents; Female; Humans; Hyperamylasemia; Injections, Intramuscular; Intubation, Gastro | 2009 |
Risperidone and pancreatitis.
Topics: Antipsychotic Agents; Child; Humans; Male; Pancreatitis; Risperidone | 2004 |
Pancreatitis associated with risperidone treatment?
Topics: Acute Disease; Adult; Humans; Male; Pancreatitis; Risperidone; Schizophrenia | 1997 |
Pancreatitis and cholestatic hepatitis induced by risperidone.
Topics: Adult; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Cholestasis; Humans; Male; Panc | 2001 |